Nomir Medical Initiates Pivotal Trial Of Its Noveon(R) Dual Wave Length Device For The Treatment Of Onychomycosis

Nomir Medical Technologies, a leader in the development of optical energy technologies for medical applications, announced the initiation of the pivotal product registration trial for the Company’s advanced Noveon® direct optical energy device. The primary objective of the trial is to test the efficacy and safety of Noveon in treating patients with onychomycosis (toenail fungus).

More: continued here

Filed under: Eye Health on May 22nd, 2008